. 2018 Jun 21;73(9):1842–1850. doi: 10.1111/all.13433

Table 2.

Quality of Life assessments during the pollen season

Measures	Treatments	N	Mean ± SD	Relative differences (%)	P‐values
Overall RQLQ Scores	Placebo	170	1.407 ± 1.104	−17.1	.005
Overall RQLQ Scores	LPP	332	1.167 ± 1.063	−17.1	.005
Activity limitations	Placebo	170	1.831 ± 1.451	−12.3	.093
Activity limitations	LPP	336	1.606 ± 1.381	−12.3	.093
Sleep problems	Placebo	170	0.914 ± 1.260	−23.1	.066
Sleep problems	LPP	336	0.702 ± 1.096	−23.1	.066
Non‐nose/eye symptoms	Placebo	170	1.240 ± 1.259	−20.9	.011
Non‐nose/eye symptoms	LPP	335	0.981 ± 1.188	−20.9	.011
Practical problem	Placebo	170	2.220 ± 1.594	−13.8	.025
Practical problem	LPP	335	1.914 ± 1.557	−13.8	.025
Nose symptoms	Placebo	170	1.875 ± 1.342	−15.3	.015
Nose symptoms	LPP	335	1.588 ± 1.276	−15.3	.015
Eye symptoms	Placebo	170	1.224 ± 1.220	−12.0	.122
Eye symptoms	LPP	332	1.076 ± 1.166	−12.0	.122
Emotional function	Placebo	170	0.860 ± 1.133	−21.2	.018
Emotional function	LPP	333	0.687 ± 1.086	−21.2	.018
Overall NRQLQ Scores	Placebo	170	0.944 ± 0.907	−16.5	.006
Overall NRQLQ Scores	LPP	338	0.789 ± 0.910	−16.5	.006
Sleep problems	Placebo	171	0.754 ± 1.077	−24.3	.014
Sleep problems	LPP	338	0.571 ± 0.961	−24.3	.014
Sleep time problems	Placebo	170	0.774 ± 0.927	−17.3	.028
Sleep time problems	LPP	339	0.640 ± 0.888	−17.3	.028
Symptoms on waking in the morning	Placebo	171	1.069 ± 1.123	−17.2	.009
Symptoms on waking in the morning	LPP	338	0.885 ± 1.121	−17.2	.009
Practical problems	Placebo	171	1.310 ± 1.004	−8.0	.025
Practical problems	LPP	339	1.205 ± 1.246	−8.0	.025

Values are shown according to the treatment planned based on observed cases. P‐values were calculated by Wilcoxon rank sum test.

LPP, Lolium perenne peptides, SD, standard deviation.